Optimization of pain management in axial apondyloarthritis: efficacy and safety of flurbiprofen in patients with comorbid post-traumatic stress disorder
Summary. Axial spondyloarthritis (AxSpA) is associated with severe pain syndrome and an inflammatory process, significantly reducing patients’ quality of life and increasing the risk of disability. Delayed or insufficient treatment may lead to substantial socio-economic losses. An important aspect of the disease is the presence of comorbid mental disorders, such as post-traumatic stress disorder (PTSD), which can complicate its course. Aim. This study aimed to evaluate the efficacy and safety of flurbiprofen in patients with AxSpA and PTSD. A total of 32 patients were included in the study, receiving flurbiprofen at a dose of 100 mg twice daily for 14 days. The assessment of efficacy was conducted using standardized clinical parameters, disease activity indices, and general clinical laboratory indicators. Results. At the early stages of therapy, flurbiprofen demonstrated a significant reduction in pain intensity and disease activity, as well as a substantial improvement in patients’ functional status. Additionally, the drug exhibited a favorable safety profile. Conclusions. Majesic-Sanovel (flurbiprofen) is an effective and safe treatment for pain syndrome in patients with AxSpA, particularly in the presence of comorbid PTSD. Due to its rapid action, prolonged analgesic effect, and favorable safety profile, it may be an optimal choice for long-term therapy in this patient population.
Leave a comment